Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;32(6):e2402.
doi: 10.1002/rmv.2402. Epub 2022 Oct 12.

Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis

Bahman Amani  1 , Behnam Amani  1
Affiliations
Review

Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis

Bahman Amani et al. Rev Med Virol. 2022 Nov.

Abstract

The therapeutic potential of sotrovimab in the treatment of coronavirus disease 2019 (COVID-19) is a controversial issue. The aim of this study was to evaluate the efficacy and safety of sotrovimab in COVID-19 patients. To this end, PubMed, Cochrane Library, Embase, Web of Science, medRxiv, and Google Scholar were searched up to 15 August 2022. The reference lists of key studies were also scanned to find additional records. Meta-analysis was performed using Comprehensive Meta-Analysis. Seventeen studies involving 27,429 patients were included. A significant difference was observed in mortality rate (odds ratio [OR] = 0.40; 95% CI: 0.25-0.63, p = 0.00), hospitalisation rate (OR = 0.53; 95% CI: 0.43-0.65. p = 0.00), hospital or death rate (OR = 0.43; 95% CI: 0.25-0.73, p = 0.00), the need for mechanical ventilation (OR = 0.57; 95% CI: 0.33-0.96, p = 0.03), and ICU admission (OR = 0.33; 95% CI: 0.17-0.67, p = 0.00) of the sotrovimab-receiving group compared to those having no sotrovimab. However, no significant difference was observed between the two groups in terms of disease progression (OR = 0.45; 95% CI: 0.16-1.24, p = 0.12) and emergency department visit (OR = 1.01; 95% CI: 0.83-1.24, p = 0.87). The two groups had no significant difference in terms of incidence of adverse events (OR = 0.98; 95% CI: 0.78-1.23, p = 0.88). The findings of the present meta-analysis support that sotrovimab could be an effective and safe treatment option to reduce mortality and hospitalisation rate in both Delta and Omicron Variants of COVID-19.

Keywords: COVID-19; SARS-CoV-2; sotrovimab.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest.

Figures

FIGURE 1
FIGURE 1
PRISMA flow diagram of the included studies in the meta‐analysis
FIGURE 2
FIGURE 2
Risk of bias assessment of the included trials
FIGURE 3
FIGURE 3
Forest plot of sotrovimab versus control for primary efficacy outcomes. (a) mortality rate. (b) hospitalisation rate. (c) Hospitalisation or death rate.
FIGURE 4
FIGURE 4
Forest plot of sotrovimab versus control for secondary efficacy outcomes. (a) ICU admission (b) mechanical ventilation (c) disease progression (d) ED visits.
FIGURE 5
FIGURE 5
Forest plot of sotrovimab versus control for incidence of adverse events
See this image and copyright information in PMC

References

    1. Akinbolade S, Coughlan D, Fairbairn R, et al. Combination therapies for COVID‐19: an overview of the clinical trials landscape. Br J Clin Pharmacol. 2022;88(4):1590‐1597. 10.1111/bcp.15089 - DOI - PMC - PubMed
    1. Selvarajan S, Anandaradje A, Shivabasappa S, Melepurakkal Sadanandan D, Nair NS, George M. Efficacy of pharmacological interventions in COVID‐19: a network meta‐analysis. Br J Clin Pharmacol. 2022;88(9):4080‐4091. 10.1111/bcp.15338 - DOI - PMC - PubMed
    1. Yamani AH, Alraddadi BM, Almaghrabi RS, et al. Early use of tocilizumab in solid organ transplant recipients with COVID‐19: a retrospective cohort study in Saudi Arabia. Immun Inflamm Dis. 2022;10(3):e587. 10.1002/iid3.587 - DOI - PMC - PubMed
    1. Gupta A, Gonzalez‐Rojas Y, Juarez E, et al. Early treatment for Covid‐19 with SARS‐CoV‐2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941‐1950. 10.1056/nejmoa2107934 - DOI - PubMed
    1. Abani O, Abbas A, Abbas F, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised, controlled, open‐label, platform trial. Lancet. 2022;399(10325):665‐676. - PMC - PubMed

Supplementary concepts